Collegium Pharmaceutical (NASDAQ:COLL) had its price target increased by stock analysts at Jefferies Group to $27.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s target price would indicate a potential upside of 59.39% from the company’s current price.

Several other equities research analysts also recently commented on the company. HC Wainwright initiated coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They set a “buy” rating and a $21.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Monday, November 13th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $14.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, September 8th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. Collegium Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $22.67.

Collegium Pharmaceutical (NASDAQ:COLL) traded down $0.06 during midday trading on Tuesday, hitting $16.94. The stock had a trading volume of 469,300 shares, compared to its average volume of 498,431. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. The firm had revenue of $11.95 million during the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The company’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.13) earnings per share. sell-side analysts expect that Collegium Pharmaceutical will post -2.56 EPS for the current year.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares in the company, valued at $8,681,068.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total value of $79,367.25. Following the sale, the insider now owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The disclosure for this sale can be found here. Insiders have sold 58,630 shares of company stock valued at $924,360 in the last quarter. 25.76% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares in the last quarter. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares in the last quarter. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares in the last quarter. Royal Bank of Canada grew its holdings in Collegium Pharmaceutical by 12.7% during the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 3,285 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Collegium Pharmaceutical by 3.4% during the first quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock worth $1,474,000 after buying an additional 4,866 shares in the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/05/collegium-pharmaceutical-coll-pt-raised-to-27-00.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

The Fly

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.